Taken together, we hypothesize that the rise in BAFF following rituximab in BEAT-lupus and CALIBRATE could trigger a wave of autoreactive IgA2 production, for instance, in the gut where IgA2 is the dominant IgA subclass. The gene discussed is CD79A; the disease is systemic lupus erythematosus.